Formulation Development
Eledon Announces Clinical Progress With Tegoprubart in the Prevention of Transplant Rejection
Eledon Pharmaceuticals, Inc. recently announced the first participant in an investigator-led clinical trial has received an islet cell transplant and is being treated with a…
MannKind Receives FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial Lung Disease
MannKind Corporation recently announced the US FDA has granted Fast Track designation of Clofazimine Inhalation Suspension (MNKD-101) for the treatment of nontuberculous mycobacterial (NTM) lung…
Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism
Lantern Pharma Inc. recently announced a strategic AI-driven collaboration with French biotechnology company, Oregon Therapeutics, to optimize the development of its first-in-class protein disulfide isomerase (PDI) inhibitor drug…
EyeDNA Therapeutics Announces Positive 24-month Data From Ongoing Phase 1/2 Trial of HORA-PDE6b Gene Therapy in Patients With Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b
eyeDNA Therapeutics recently announced positive 24-month follow-up results from its Phase 1/2 study (NCT03328130) evaluating the safety and efficacy of HORA-PDE6b, its investigational gene therapy…
Enable Injections Expands Strategic Partnership With Roche
Enable Injections, Inc. recently announced it has expanded its partnership with Roche through a collaboration, allowing Roche to develop and apply Enable’s expertise….
DevPro Biopharma & Bespak Complete Early Feasibility Studies for New Groundbreaking Albuterol Inhaler
DevPro Biopharma and Bespak have recently announced the completion of early feasibility studies on DP007, a new formulation of albuterol in a pressurized metered dose….
Creyon Bio to Present Clinical Data on Rapid AI-Enabled Engineering of Oligonucleotide-Based Medicines
Creyon Bio, Inc. recently announced encouraging clinical data highlighting the use of its custom designed data set paired with artificial intelligence (AI) to rapidly engineer…
Inmagene Announces Completion of Enrollment in Phase 2a Trial of a Nondepleting & Half-Life Extended Anti-OX40 Monoclonal Antibody
Inmagene Biopharmaceuticals recently announced it completed target enrollment in its Phase 2a trial evaluating IMG-007 in adult patients with AA. IMG-007 is a nondepleting anti-OX40…
Bespak & H&T Presspart Enter Collaboration Agreement to Advance Transition to Low GWP Propellants in pMDIs
Partnership will provide GMP filling capabilities and development support for clinical trial programs with low GWP propellants….
Bespak & Medicines Evaluation Unit Collaborate to Accelerate Clinical Trials on Climate-Friendly Inhalers
Bespak and The Medicines Evaluation Unit (MEU) recently announced a collaboration to further accelerate the pharmaceutical industry’s transition from existing pressurized Metered Dose Inhaler (pMDI)…
WHITEPAPER - Continuous Flow - An Emerging Alternative
In the whitepaper Continuous Flow: An Emerging Alternative, Curia experts discuss how continuous flow chemistry and processing offer an alternative pathway. The paper explores its….
Medigene AG Expands Patent Portfolio With Patent Grant for its Targeted T Cell Receptor
Medigene AG recently announced it has been issued a patent by the European Patent Office protecting its T cell receptor (TCR) targeting NY-ESO-1….
Guangzhou Bio-gene Technologies Announces Initiation of Phase 1 Clinical Trial for CAR-T Targeting CLL-1
Guangzhou Bio-gene Technologies recently announced the first patient was treated with BG1805, an investigational autologous CAR-T cell therapy targeting CLL-1, a member of the C-type…
Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit & Achieves Significant Milestone With Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer
Allarity Therapeutics, Inc. recently announced the early discontinuation of its Phase 2 clinical trial of stenoparib, a novel PARP inhibitor, for the treatment of advanced…
Pluri Launches Novel Immunotherapy Platform for Solid Tumor Treatment
Pluri Inc. recently launched its placental allogeneic MAIT cell platform for immunotherapy treatment for solid tumors – a significant medical need which currently lacks effective…
ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics
ASLAN Pharmaceuticals recently announced it has signed a new research collaboration agreement with its partner, Zenyaku Kogyo Co., Ltd., to establish a framework for a…
INmune Bio Provides Update on Two Patients From Phase 1b Alzheimer’s Disease Trial Who Continue to Receive XPro Under Compassionate Use for Over 3 Years
INmune Bio Inc. recently shared an update on two patients from the Phase 1b trial completed in 2021 who have continued to receive XPro for…
Editas Medicine & Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
Editas Medicine, Inc. recently announced a 2-year extension to the collaboration with Bristol Myers Squibb under which the parties may research, develop, and commercialize autologous…
Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
Denali Therapeutics Inc. recently announced that the Sean M. Healey & AMG Center in collaboration with the Northeast ALS Consortium (NEALS) completed enrollment for Regimen…
Creyon Bio & Cajal Neuroscience Announce Partnership to Develop Oligonucleotide-Based Medicines for Neurodegenerative Diseases
Creyon Bio, Inc. and Cajal Neuroscience recently announced a partnership to develop novel OBMs for neurodegenerative diseases. Under the collaboration, the companies are developing antisense…
